by Biocross | Nov 12, 2015 | Press release
Biocross presents a fast and cost-effective method for apolipoprotein E isotyping as an alternative to APOE genotyping for patient stratification in clinical trials at the 2015 Clinical Trials for Alzheimer’s disease (CTAD) meeting in November 2015. Isoform E4 of...
by Biocross | Mar 26, 2015 | News
Early diagnosis of this disease is one of the factors that would enable better treatment. This is a key focus of many of the biotechnology companies that have emerged in recent decades. In Spain and in other countries, several research projects are currently underway,...
by Biocross | Nov 20, 2014 | Press release
Biocross S.L., an innovative developer of assays for risk assessment and prediction of AD, has announced that it will be presenting a poster at the Clinical Trials on Alzheimer’s disease Conference, CTAD 2014, Philadelphia, United States, November 20-22nd, discussing...
by Biocross | Sep 29, 2014 | Press release
Biocross is involved in a new multicenter study in which 17 hospitals from Spain, France, and Belgium are participating. The objective is to recruit over 500 patients, classified as healthy individuals or patients with AD, mild cognitive impairment, or other...
by Biocross | Nov 27, 2013 | News
The company recently completed a multicenter exploratory study in which seven Spanish hospitals participated, to identify markers of the disease. The study involved 306 patients. More...
